Massachusetts General Hospital logoPsychosis Consultation ServiceDepartment of Psychiatry
Back to what we provide

Medication strategy & safety

Why Medication Strategy and Safety Matter

Antipsychotic medication is an important part of schizophrenia treatment. The right medication plan can help control symptoms, prevent relapse, and support long-term recovery. However, the medication must also be safe, tolerable, and realistic for the person to continue taking.

Continue to key points

Reasons medication strategy and safety matter

  • Effective medication helps prevent relapse and hospitalization.

    People who continue an effective antipsychotic treatment are much less likely to experience a return of psychosis or need hospitalization than people who stop treatment.

  • Relapse can disrupt recovery.

    A return of psychosis can interrupt school or work, strain relationships, destabilize housing, reduce independence, and sometimes require hospitalization.

  • Medication choice should be individualized.

    Different antipsychotics have different benefits and risks. The best option depends on the person’s previous response, medical history, daily routine, treatment goals, and preferences.

  • Side effects must be actively managed.

    Problems such as weight gain, movement symptoms, sedation, or changes in blood sugar and cholesterol should be monitored and treated early rather than accepted as an unavoidable part of schizophrenia care.

  • A specialty consultation can help find the most effective and sustainable plan.

    The evaluation can review medication effectiveness, dose, missed doses, interactions, side effects, oral and long-acting injectable options, and opportunities to simplify treatment. The goal is not more medication. It is the safest and most effective plan that the patient can realistically continue.

Evidence snapshot

Why an effective maintenance plan matters

27% vs. 64%
Across 65 randomized trials, relapse at one year occurred in 27% of people who continued antipsychotic medication and 64% of those assigned to placebo after stabilization.[1]
10% vs. 26%
In the same meta-analysis, hospital readmission occurred in 10% of people receiving maintenance medication and 26% receiving placebo.[1]

These trial averages do not predict an individual patient’s outcome. Medication benefits must be weighed against side effects, and medication should not be stopped without guidance from the treating clinician.

References

  1. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-71.
  2. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77.
  3. Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease—a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry. 2014;5:137.
  4. Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248-71.